Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Both healthcare giants are among the most elite dividend stocks on the market. AbbVie can handle the biosimilar challenges to Humira without it breaking the company.

Better Dividend Stock: AbbVie vs. Johnson & Johnson

Broadcom

Vici Properties

AbbVie's drug portfolio and pipeline bode well for future growth. Consumers value experiences more than stuff, which could benefit VICI Properties and its tenants.

Want to Collect Big Dividends Each Month? Buy These 3 Stocks

Crocs

CVS Health

UnitedHealth Group

United Therapeutics

Williams

With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in developed as well as emerging markets.

A Look at Bernard Horn's Top Holdings Ahead of Value Conference

NORTH CHICAGO, Ill. , April 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

AbbVie to Host First-Quarter 2023 Earnings Conference Call

Realty Income Corp

Mr. Valuation has been almost like a college professor for our team of analysts, always adhering to the timeless principles of the margin of safety. Mr. Valuation explains that the dividend received from a publicly traded company represents significant investment benefits.

3 Dividend Aristocrats That Generate Income For Life

LAUNCHES THE COOLEST PROMOTION WITH A BUY 4, GET 4 DEAL AT PARTICIPATING PROVIDERS TO SUPPORT YOUR BODY CONTOURING JOURNEY IRVINE, Calif. , April 3, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and the parent company of CoolSculpting® Elite, announces the first ever CoolMonth, taking place this April.

CoolSculpting® Elite Announces First Ever CoolMonth

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Devon Energy

Enterprise Products Partners

Medical Properties Trust

Five stocks should generate an average yield of 8.45% on an investment of around $36,100. In addition to high dividend yields, these stocks offer attractive valuations and long-term growth prospects.

These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year

Rinvoq recently moved into phase 3 clinical trials for what could be its seventh indication. If approved, it could generate almost $400 million in additional yearly revenue for the drugmaker.

Could This Drug News Lift AbbVie's Stock?

Mercedes-Benz Group AG

Altria

Suncor Energy

TotalEnergies SE

U.S. Bancorp

Toronto-Dominion Bank

Verizon

In today's article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. The 10 selected picks provide you with an attractive Dividend Yield, a relatively low Payout Ratio, as well as important competitive advantages and strong Financials.

My Top 10 High Dividend Yield Stocks To Invest In April 2023

Skyrizi's recently announced phase 3 clinical trial results to treat ulcerative colitis demonstrate that it is effective. An ulcerative colitis indication in the U.S. could be a blockbuster all on its own.

This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

Coca-Cola

Coca-Cola and AbbVie are two solid investments that pay more than 3% in dividends. Coca-Cola's growth rate has been impressive at a challenging time, and is well above its 10-year high.

2 High-Yielding Dividend Investments to Buy for the Long Haul

Vertex Pharmaceuticals

Vertex and AbbVie both beat the bear market last year. Both these top companies have reached an important moment in their stories -- and more growth may be on the horizon.

Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie

-- 'Discover Your 360°' immersive experience to feature across Allergan Aesthetics events, supporting customers with all aspects of their Practice, Product and Patient needs -- -- Two expert-led Allergan Medical Institute (AMI) symposia to discuss a 360° approach to consultation and treatment, featuring live injection sessions with Dr.Mauricio de Maio and Dr. Sylwia Lipko-Godlewska – IRVINE, Calif. , March 29, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world.

Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

Pfizer

AbbVie might not grow much in 2023 and 2024. Pfizer will see tens of billions of its sales evaporate soon.

Better Growth Stock: AbbVie vs. Pfizer

Abbott Labs

Automatic Data Processing

Aflac

A. O. Smith

Air Products and Chemicals

Franklin Resources

Cardinal Health

Caterpillar

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Expeditors International of Washington

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Kimberly-Clark

New Linde PLC

Lowe's

I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.

Selecting Dividend Aristocrats Using SCHD Methodology - Mounting A Comeback

Best Stocks To Buy Today? 3 Top Dividend Stocks To Watch

NextEra Energy

Companies that hike their dividends over and over tend to be financially healthy. AbbVie's good track record with commercializing medicines is likely to continue.

2 Relatively Safe Dividend Stocks You Won't Regret Owning

ETFs provide stability and diversification to a portfolio.

This Is the Best Dividend ETF You Can Buy

Brookfield Renewable Partners

DoubleLine Yield Opportunities Fund

Innovative Industrial Properties

ONEOK

Viatris

The group of 12 high-yielders consists of pharma stocks, oil and gas stocks, REITs, and more. Several of them face higher risks than others.

I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.

AbbVie and J&J both are facing big transitions this year. These stocks look inexpensive today, both trading at around 14 times forward earnings estimates.

Better Buy: AbbVie vs. Johnson & Johnson

News for AbbVie Stock (ABBV)